DASbox® Mini Bioreactor System: In the Quality by Design (QbD) and Process Analytical Technology (PAT) era, the generation and validation of a large amount of data have become standard. Parallel bioreactor control systems offer the possibility to test and optimize different process parameters at the same time, thus saving time and resources.
Knowledge Gain Through High Parallel Bioprocess Setups
ProductsDASbox® Mini Bioreactor System: In the Quality by Design (QbD) and Process Analytical Technology (PAT) era, the generation and validation of a large amount of data have become standard. Parallel bioreactor control systems offer the possibility to test and optimize different process parameters at the same time, thus saving time and resources.
New CEO of the Novo Nordisk Foundation
AppointmentsMads Krogsgaard Thomsen, CSO at Novo Nordisk, will take up the position as CEO of the Novo Nordisk Foundation effective from 1 March 2021.
Biomarker identifies high-risk COVID-19 patients
Latest NewsAustrian researchers have found that a lack of activation of the NK receptor is highly associated with severe COVID-19 disease courses.
Management changes at Abliva
AppointmentsLund-based Abliva AB named Dr Ellen Donnelly as its new CEO. At the beginning of February she succeeded Dr Erik Kinnmann, who had been CEO since 2018.
MaxiVAX and Minaris Regenerative Medicine ink contract
Latest NewsSwiss cancer vaccine specialist MaxiVAX SA has hired Minaris Regenerative Medicine GmbH to produce its cell therapy MVX-ONCO-2.
EU orders additional COVID-19 vaccine doses
Latest NewsPfizer Inc. and BioNTech SE have signed an agreement with the European Commission (EC) to supply an additional 200 million doses of BNT162b2 to the EU.
Novel strategy targets chronic liver diseases
Latest NewsA resesarch team headed by HepaRegeneriX Board Member Lars Zender has presented a new approach to treat hepatocellular carcinoma (HCC) by disturbing the lipid metabolism of tumour cells.
Swedish AlzeCure appoints CMO
AppointmentsMärta Segerdahl will take over the position as Chief Medical Officer of Swedish AlzeCure Pharma AB on April.
Cellectis and Cytovia in US$760m licence deal
Latest NewsCell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.
Higher omega-3 level apparently protects from dying from COVID-19
Sponsored Publications